Literature DB >> 14586542

Inhibition of fear potentiated startle in rats following peripheral administration of secretin.

Karyn Myers1, Martin Goulet, James Rusche, Richard Boismenu, Michael Davis.   

Abstract

RATIONALE: Previous results indicate that peripheral administration of secretin leads to robust Fos protein expression in the central nucleus of the rat amygdala. The implications of this observation on rat brain function, if any, remain unclear.
OBJECTIVES: We examined the effect of systemic secretin administration on the expression of fear-potentiated startle in rats, a behavioral response known to require an intact, functional central nucleus of the amygdala.
METHODS: Rats were trained to associate a neutral light conditioned stimulus (CS) with footshock, a fear-inducing unconditioned stimulus (US). Twenty-four hours later, rats were administered secretin or vehicle and were tested immediately for their startle response to a loud noise in the presence or absence of the light.
RESULTS: Within a dose range relevant to its clinical use in autistic children, secretin dose-dependently decreased the magnitude of fear-potentiated startle in rats.
CONCLUSIONS: This investigation provides additional evidence that systemically administered secretin can influence a neural network implicated in the acquisition and expression of emotional behaviors, including fear and anxiety.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14586542     DOI: 10.1007/s00213-003-1633-5

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Convergent neuroanatomical and behavioural evidence of an amygdala hypothesis of autism.

Authors:  M A Howard; P E Cowell; J Boucher; P Broks; A Mayes; A Farrant; N Roberts
Journal:  Neuroreport       Date:  2000-09-11       Impact factor: 1.837

2.  Secretin stimulates cyclic AMP formation in the rat brain.

Authors:  R T Fremeau; L Y Korman; T W Moody
Journal:  J Neurochem       Date:  1986-06       Impact factor: 5.372

3.  Localization and possible function of peptidergic neurons and their interactions with central catecholamine neurons, and the central actions of gut hormones.

Authors:  K Fuxe; K Andersson; T Hökfelt; V Mutt; L Ferland; L F Agnati; D Ganten; S Said; P Eneroth; J A Gustafsson
Journal:  Fed Proc       Date:  1979-08

4.  A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism.

Authors:  S J Coniglio; J D Lewis; C Lang; T G Burns; R Subhani-Siddique; A Weintraub; H Schub; E W Holden
Journal:  J Pediatr       Date:  2001-05       Impact factor: 4.406

5.  Secretin at physiological doses inhibits gastric motility via a vagal afferent pathway.

Authors:  Y Lu; C Owyang
Journal:  Am J Physiol       Date:  1995-06

6.  Intrinsic photoaffinity labeling of native and recombinant rat pancreatic secretin receptors.

Authors:  C D Ulrich; D I Pinon; E M Hadac; E L Holicky; A Chang-Miller; L K Gates; L J Miller
Journal:  Gastroenterology       Date:  1993-11       Impact factor: 22.682

7.  Presence and possible site of action of secretin in the rat pituitary and hypothalamus.

Authors:  W K Samson; M D Lumpkin; S M McCann
Journal:  Life Sci       Date:  1984-01-09       Impact factor: 5.037

8.  Histoanatomic observations of the brain in early infantile autism.

Authors:  M Bauman; T L Kemper
Journal:  Neurology       Date:  1985-06       Impact factor: 9.910

9.  Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family.

Authors:  G V Segre; S R Goldring
Journal:  Trends Endocrinol Metab       Date:  1993-12       Impact factor: 12.015

10.  Differential transport of a secretin analog across the blood-brain and blood-cerebrospinal fluid barriers of the mouse.

Authors:  William A Banks; Martin Goulet; James R Rusche; Michael L Niehoff; Richard Boismenu
Journal:  J Pharmacol Exp Ther       Date:  2002-09       Impact factor: 4.030

View more
  8 in total

Review 1.  Brain meets body: the blood-brain barrier as an endocrine interface.

Authors:  William A Banks
Journal:  Endocrinology       Date:  2012-07-09       Impact factor: 4.736

Review 2.  Distribution and Functional Implication of Secretin in Multiple Brain Regions.

Authors:  Ruanna Wang; Billy K C Chow; Li Zhang
Journal:  J Mol Neurosci       Date:  2018-06-07       Impact factor: 3.444

3.  Brain effects of chronic IBD in areas abnormal in autism and treatment by single neuropeptides secretin and oxytocin.

Authors:  Martha G Welch; Thomas B Welch-Horan; Muhammad Anwar; Nargis Anwar; Robert J Ludwig; David A Ruggiero
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

4.  A functional variable number of tandem repeats is located at the 5' flanking region of the human secretin gene plays a downregulatory role in expression.

Authors:  Leo T O Lee; Ian P Y Lam; Billy K C Chow
Journal:  J Mol Neurosci       Date:  2008-06-20       Impact factor: 3.444

5.  The neurotensin-1 receptor agonist PD149163 blocks fear-potentiated startle.

Authors:  Paul D Shilling; David Feifel
Journal:  Pharmacol Biochem Behav       Date:  2008-10       Impact factor: 3.533

6.  Center for Behavioral Neuroscience: a prototype multi-institutional collaborative research center.

Authors:  Kelly R Powell; H Elliott Albers
Journal:  J Biomed Discov Collab       Date:  2006-07-17

Review 7.  Involvement of Secretin in the Control of Cell Survival and Synaptic Plasticity in the Central Nervous System.

Authors:  Lei Wang; Li Zhang
Journal:  Front Neurosci       Date:  2020-05-06       Impact factor: 4.677

8.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.